Published in Rev Esp Cardiol on December 01, 2011
Clinical Impact of Rapid Reduction of Low-Density Lipoprotein Cholesterol Level on Long-Term Outcome of Acute Myocardial Infarction in the Statin Era: Subanalysis of the ALPS-AMI Study. PLoS One (2015) 0.81
Whole-exome sequencing in an extended family with myocardial infarction unmasks familial hypercholesterolemia. BMC Cardiovasc Disord (2014) 0.80
Systematic analysis of variants related to familial hypercholesterolemia in families with premature myocardial infarction. Eur J Hum Genet (2015) 0.78
Combined use of probucol and cilostazol with atorvastatin attenuates atherosclerosis in moderately hypercholesterolemic rabbits. Lipids Health Dis (2015) 0.77
Comment to the position paper on global recommendations for the management of dyslipidemia developed by the International Atherosclerosis Society (IAS). Atherosclerosis (2014) 0.75
Development of job standards for clinical nutrition therapy for dyslipidemia patients. Clin Nutr Res (2015) 0.75
[Comments on the ESC/EAS guidelines for the management of dyslipidaemias 2011. A report of the Task Force of the Clinical Practice Guidelines Committee of the Spanish Society of Cardiology]. Rev Esp Cardiol (2011) 0.75
Polydextrose changes the gut microbiome and attenuates fasting triglyceride and cholesterol levels in Western diet fed mice. Sci Rep (2017) 0.75
Post-mortem investigation of young deceased individuals with ischemic heart disease-outcome of supplementary genetic testing for dyslipidemia. Int J Legal Med (2015) 0.75
Genome-wide association analysis identifies loci for type 2 diabetes and triglyceride levels. Science (2007) 51.70
Six new loci associated with blood low-density lipoprotein cholesterol, high-density lipoprotein cholesterol or triglycerides in humans. Nat Genet (2008) 20.73
2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2007) 20.09
2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens (2013) 18.17
Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med (2009) 18.03
2013 ESH/ESC guidelines for the management of arterial hypertension: the Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2013) 12.73
ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J (2011) 10.52
2007 Guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Eur Heart J (2007) 9.43
Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med (2015) 8.69
Third universal definition of myocardial infarction. J Am Coll Cardiol (2012) 8.59
European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and Other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur Heart J (2003) 8.51
European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 6.10
Cardiovascular prevention guidelines in daily practice: a comparison of EUROASPIRE I, II, and III surveys in eight European countries. Lancet (2009) 5.84
Guidelines on the management of stable angina pectoris: executive summary: The Task Force on the Management of Stable Angina Pectoris of the European Society of Cardiology. Eur Heart J (2006) 5.79
Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med (2014) 5.25
Defining knowledge translation. CMAJ (2009) 5.11
Reappraisal of European guidelines on hypertension management: a European Society of Hypertension Task Force document. J Hypertens (2009) 4.87
Effects of Proprotein Convertase Subtilisin/Kexin Type 9 Antibodies in Adults With Hypercholesterolemia: A Systematic Review and Meta-analysis. Ann Intern Med (2015) 4.62
2007 ESH-ESC Practice Guidelines for the Management of Arterial Hypertension: ESH-ESC Task Force on the Management of Arterial Hypertension. J Hypertens (2007) 4.59
Lipoprotein(a) as a cardiovascular risk factor: current status. Eur Heart J (2010) 4.31
Common missense variant in the glucokinase regulatory protein gene is associated with increased plasma triglyceride and C-reactive protein but lower fasting glucose concentrations. Diabetes (2008) 4.20
Identification of seven loci affecting mean telomere length and their association with disease. Nat Genet (2013) 3.87
Subendothelial retention of atherogenic lipoproteins in early atherosclerosis. Nature (2002) 3.80
Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: consensus statement of the European Atherosclerosis Society. Eur Heart J (2013) 3.58
Effect of two intensive statin regimens on progression of coronary disease. N Engl J Med (2011) 3.52
Noninvasive (input) impedance, pulse wave velocity, and wave reflection in healthy middle-aged men and women. Hypertension (2007) 3.43
European guidelines on cardiovascular disease prevention in clinical practice: third joint task force of European and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of eight societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2003) 3.43
Impaired endothelial function in persons with obstructive sleep apnoea: impact of obesity. Heart (2012) 3.36
Cholesteryl ester transfer protein: a novel target for raising HDL and inhibiting atherosclerosis. Arterioscler Thromb Vasc Biol (2003) 3.26
Functionally defective high-density lipoprotein: a new therapeutic target at the crossroads of dyslipidemia, inflammation, and atherosclerosis. Pharmacol Rev (2006) 3.26
Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med (2011) 3.20
EUROASPIRE III: a survey on the lifestyle, risk factors and use of cardioprotective drug therapies in coronary patients from 22 European countries. Eur J Cardiovasc Prev Rehabil (2009) 3.19
Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management. Eur Heart J (2011) 3.00
Predictors of and longitudinal changes in insulin sensitivity and secretion preceding onset of type 2 diabetes. Diabetes (2005) 2.99
Comparison of ticagrelor with clopidogrel in patients with a planned invasive strategy for acute coronary syndromes (PLATO): a randomised double-blind study. Lancet (2010) 2.98
Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome. Arterioscler Thromb Vasc Biol (2008) 2.96
ESC/EAS Guidelines for the management of dyslipidaemias The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis (2011) 2.90
Familial combined hyperlipidemia is associated with upstream transcription factor 1 (USF1). Nat Genet (2004) 2.86
Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation (2009) 2.84
One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care (2009) 2.75
Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. Diabetes Care (2008) 2.73
European guidelines on cardiovascular disease prevention in clinical practice: executive summary. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts). Eur J Cardiovasc Prev Rehabil (2007) 2.70
2013 ESH/ESC Practice Guidelines for the Management of Arterial Hypertension. Blood Press (2013) 2.62
Comparative effects of antiplatelet, anticoagulant, or combined therapy in patients with valvular and nonvalvular atrial fibrillation: a randomized multicenter study. J Am Coll Cardiol (2004) 2.60
Amplification of the pressure pulse in the upper limb in healthy, middle-aged men and women. Hypertension (2009) 2.59
Apo B versus cholesterol in estimating cardiovascular risk and in guiding therapy: report of the thirty-person/ten-country panel. J Intern Med (2006) 2.55
Postreceptor insulin resistance contributes to human dyslipidemia and hepatic steatosis. J Clin Invest (2009) 2.53
Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: a prospective registry study. Eur Heart J (2008) 2.50
Proteomic analysis of defined HDL subpopulations reveals particle-specific protein clusters: relevance to antioxidative function. Arterioscler Thromb Vasc Biol (2009) 2.50
Response to ticagrelor in clopidogrel nonresponders and responders and effect of switching therapies: the RESPOND study. Circulation (2010) 2.46
HDL measures, particle heterogeneity, proposed nomenclature, and relation to atherosclerotic cardiovascular events. Clin Chem (2011) 2.33
Non-vitamin K antagonist oral anticoagulants (NOACs): No longer new or novel. Thromb Haemost (2014) 2.29
Achievement of treatment goals for primary prevention of cardiovascular disease in clinical practice across Europe: the EURIKA study. Eur Heart J (2011) 2.29
A comparison of the quality of Cochrane reviews and systematic reviews published in paper-based journals. Eval Health Prof (2002) 2.29
Metabolic syndrome in type 1 diabetes: association with diabetic nephropathy and glycemic control (the FinnDiane study). Diabetes Care (2005) 2.26